logo
Share SHARE
FONT-SIZE Plus   Neg

Seattle Genetics Initiates Phase 2 Trial Of Adcetris In Combination With RCHOP

Seattle Genetics Inc. (SGEN) announced the initiation of a phase 2 clinical trial evaluating Adcetris (brentuximab vedotin) in combination with RCHOP (A+RCHOP), the current standard frontline therapy, for newly diagnosed patients with diffuse large B-cell lymphoma or DLBCL.

The study is intended to evaluate the complete remission rate and safety of the A+RCHOP regimen. Adcetris is an antibody-drug conjugate or ADC directed to CD30. Adcetris is currently not approved for the treatment of DLBCL.

According to the company, in this phase 2, open-label clinical trial, approximately 50 frontline high-risk DLBCL patients will receive ADCETRIS in combination with the standard of care consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (A+RCHOP). Patients will be randomized to receive standard dose RCHOP with either 1.2 milligrams per kilogram (mg/kg) or 1.8 mg/kg of Adcetris.

The company noted that the trial will enroll patients regardless of CD30 expression level by immunohistochemistry or IHC to further explore previously reported interim data from an ongoing phase 2 trial for relapsed B-cell lymphomas, including DLBCL, demonstrating objective responses in patients with varying levels of CD30.

The primary endpoints are to assess the complete remission rate and safety profile of the combination. Secondary endpoints include objective response rate, progression-free survival and overall survival.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Several flights to the Indonesian tourist island Bali were canceled due to volcanic ashes from the Mount Raung. Virgin airlines canceled all the flights to Denpasar Airport, while Jetstar rescheduled three flights to Perth and Melbourne in Australia. Activision Blizzard reported a better-than-expected increase in second-quarter profit, as the video game publisher saw robust growth in digital channels, penetration in China and improved margins. It lifted its guidance for 2015, sending its shares up... Diversified media and entertainment conglomerate Walt Disney Co. said Tuesday after the markets closed that its third quarter profit rose 11% from last year, driven mainly by strong earnings growth at its film and consumer products divisions. The company's quarterly earnings per share came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast.
comments powered by Disqus
Follow RTT